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Abstract
Purpose Multiple imaging techniques are nowadays available
for clinical in-vivo visualization of tumour biology. FDG
PET/CT identifies increased tumour metabolism, hypoxia
PET visualizes tumour oxygenation and dynamic contrast-
enhanced (DCE) CT characterizes vasculature and morpholo-
gy. We explored the relationships among these biological fea-
tures in patients with non-small-cell lung cancer (NSCLC) at
both the patient level and the tumour subvolume level.
Methods A group of 14 NSCLC patients from two ongoing
clinical trials (NCT01024829 and NCT01210378) were
scanned using FDG PET/CT, HX4 PET/CT and DCE CT
prior to chemoradiotherapy. Standardized uptake values
(SUV) in the primary tumour were calculated for the FDG
and hypoxia HX4 PET/CT scans. For hypoxia imaging, the
hypoxic volume, fraction and tumour-to-blood ratio (TBR)
were also defined. Blood flow and blood volume were obtain-
ed from DCE CT imaging. A tumour subvolume analysis was
used to quantify the spatial overlap between subvolumes.
Results At the patient level, negative correlations were ob-
served between blood flow and the hypoxia parameters
(TBR >1.2): hypoxic volume (−0.65, p=0.014), hypoxic frac-
tion (−0.60, p=0.025) and TBR (−0.56, p=0.042). At the
tumour subvolume level, hypoxic and metabolically active
subvolumes showed an overlap of 53±36%. Overlap between
hypoxic sub-volumes and those with high blood flow and
blood volume was smaller: 15±17 % and 28±28 %, respec-
tively. Half of the patients showed a spatial mismatch (overlap
<5 %) between increased blood flow and hypoxia.
Conclusion The biological imaging features defined in
NSCLC tumours showed large interpatient and intratumour
variability. There was overlap between hypoxic and metabol-
ically active subvolumes in the majority of tumours, there was
spatial mismatch between regions with high blood flow and
those with increased hypoxia.
Keywords DCECT .HypoxiaPET .HX4 .FDGPET .Image
analysis . Multiparametric
Introduction
Locally advanced stage non-small-cell (NSCLC) lung cancer
still has a poor prognosis, despite more advanced and aggres-
sive treatment strategies consisting of a combination of che-
motherapy and radiotherapy. Integrated 18F-FDG PET/CT of
NSCLC is recommended for assessment of the primary
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tumour extension, and detection of regional lymph node me-
tastases and possibly distant metastases. Tumour heterogene-
ity assessed by noninvasive imaging might be helpful in guid-
ing treatment planning and optimizing outcome [1–6]. High
levels of hypoxia and metabolic activity are linked to a poor
prognosis. Furthermore, as known from histology, vascular
parameters such as blood flow and blood volume are de-
creased in hypoxic tumours [7].
Several imaging modalities are currently available for iden-
tifying different, biologically heterogeneous regions. Tumour
metabolism can be imaged using FDG PET and is a known
prognostic marker for outcome. Response assessment with
repeated FDG PET/CT has been shown to have predictive
power in NSCLC [8, 9]. Hypoxia is another well-known char-
acteristic of solid tumours that has negative effects on sensi-
tivity to radiotherapy and chemotherapy, while increasing the
metastatic potential of cancer cells. Imaging of hypoxia is
currently possible using nitroimidazole-based PET tracers
such as FMISO or HX4 [10–12]. Perfusion of tumours is
important in supplying the tumour with nutrients and oxygen
for expansive growth. In addition, targeted agents have been
developed that influence perfusion of the tumour by inhibition
of angioneogenesis [13]. Imaging of vascular properties of
tumours is technically feasible using dynamic contrast-
enhanced (DCE) CTor DCEMRI that allow the characteriza-
tion of various vascular parameters such as blood flow and
permeability [14, 15].
The clinical benefit of multiparametric imaging may allow
comprehensive assessment of the biological status of the tu-
mour that can subsequently be used for individualized therapy.
Especially with newly developed chemotherapy and agents
targeting specific biological characteristics, such as hypoxia
within the tumour, that are currently under investigation, the
use of molecular imaging for treatment selection and response
assessment has become important [16]. Furthermore, using
modern radiotherapy techniques it is possible to modulate
the radiation dose in the tumour volume to boost subvolumes
that are likely to be more therapy-resistant [17–20].
Therefore, in this study we investigated multiple imaging
techniques to assess the metabolic, hypoxic and vascular sta-
tus of the primary tumour in a cohort of patients with ad-
vanced stage NSCLC.We performed an analysis at the patient
level to compare the various biological characteristics in the
primary tumours. Next, we investigated possible correlations
at the subvolume level of the primary tumour for each indi-
vidual patient to identify spatial agreement (or mismatch) at
the tumour subvolume level.
Materials and methods
Patients with stage II–IV NSCLC were included from two
ongoing therapeutic clinical trials (NCT01024829 and
NCT01210378) that have the same pretreatment imaging pro-
cedures. Apart from the standard FDG PET/CT imaging for
radiation treatment planning, patients received an additional
DCE CT scan and a hypoxia HX4 PET/CT scan. Preferably,
the DCE CT and HX4 PET/CT scans were acquired on the
same day. The FDG PET/CT scan for treatment planning pur-
poses was obtained in the same week and typically prior to the
other scans. The study was approved by the appropriate med-
ical ethics committee, and written and signed informed con-
sent was obtained from all individual participants included in
the studies.
FDG PET/CT acquisition
The FDG PET/CT scan was acquired on a Biograph 40 PET/
CT scanner (Siemens Healthcare, Forchheim, Germany) 1 h
after injection of approximately 250 MBq FDG. Reconstruc-
tion settings for the PET scan were based on an iterative re-
construction algorithm with attenuation and scatter correction
(OSEM, four iterations, eight subsets, using a 5-mmGaussian
filter) on a 168×168 (4×4 mm) grid and a slice thickness of
3 mm . The FDG PET/CT imaging procedure was accredited
following EANM/EARL guidelines [21]. A respiration-
correlated (4D) CT scan was acquired on the PET/CT scanner
with the midventilation phase of the CT scan used for PET
attenuation correction. The midventilation phase was fused
with the FDG PET images and used for contouring the gross
tumour volume necessary for radiation treatment planning.
Dynamic contrast-enhanced CTacquisition
The DCE CT acquisition was performed on a second-
generation dual source CT scanner (SOMATOM Definition
Flash; Siemens Healthcare) using a previously described ac-
quisition protocol [22]. In brief, the CT scan comprised a first-
pass volumetric perfusion acquisition with a serial acquisition
every 1.5 s at 80 kVp CT of the part of the thorax centred on
the primary tumour (scan length 12 cm) for a period of ap-
proximately 50 s (33 consecutive scans). Patients were imaged
in expiration breath-hold and asked to continue shallow
breathing if holding their breath was no longer possible. Pa-
tients received 60ml of iodinated contrast medium (Iopromide
300; Bayer Healthcare, Berlin, Germany) at a flow rate of
7 ml/s (iodine delivery rate 2.1 g/s), followed by a saline
chaser of 30 ml at the same flow rate. CT images were recon-
structed using a B20f filter with a slice thickness of 5 mm and
a slice increment of 3 mm. CT images were registered after-
wards to correct for breathing motion and a deconvolution
approach was used for the kinetic modelling of the perfusion
parameters implemented in commercially available software
(Siemens VPCT body; Siemens Healthcare). The perfusion
parameters blood flow (ml/100 ml/min) and blood volume
(ml/100 ml) were extracted. A detailed description of the
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imaging and analysis techniques for DCE CT imaging has
recently been described [23, 24].
Hypoxia HX4 PET/CT scan
Hypoxia PET imaging was performed using the hypoxia PET
tracer HX4 (Threshold Pharmaceuticals). The characteristics
of this tracer and acquisition details have been described else-
where [25]. A dose of approximately 440 MBq of HX4 was
administered intravenously. The scan acquired at 4 h after
injection was used for analysis. Images were acquired using
a time-of-flight PET/CT scanner (Gemini TF64; Philips,
The Netherlands) with reconstructed images (BLOB-OS-TF,
three iterations, 33 subsets) having an in-plane pixel spacing
of 4 mm at a slice thickness of 4 mm without overlap.
Image preprocessing
For the FDG PET and HX4 PET scans, the image intensities
were converted to standardized uptake values (SUV)
correcting for decay, injected dose and bodyweight. Addition-
ally for the hypoxia PETscans, a region of interest in the aorta
was drawn to normalize tumour uptake to the average back-
ground uptake in the blood pool. A tumour-to-blood ratio
(TBR) was calculated for every voxel. The hypoxic fraction
and volume were then calculated using a TBR >1.2 and TBR
>1.4 within the volume of the primary tumour. Next all CT
scans were nonrigidly registered to the CT scan of the FDG
PET/CT scan using a previously validated deformable regis-
tration algorithm [26–28]. The hypoxia PET image and DCE
CTextracted kinetic parameter maps were registered using the
CT-derived deformation field for that dataset. All deformation
fields were visually inspected and approved.
Multiparametric image analysis
In total four parameter maps, including the metabolic FDG
PET scan, the hypoxic HX4 PET scan and two parameters
derived from the DCE CT imaging (blood flow and blood
volume), were investigated for correlations. Analysis was per-
formed at two levels: correlation at the patient level and in-
vestigation at the tumour subvolume level. First, at the patient
level we investigated the average uptake or signal of the four
parameter maps at the global tumour level. For this we calcu-
lated the average of the parameter maps within the primary
tumour, i.e. mean SUVof FDG uptake, average TBR, hypoxic
volume and hypoxic fraction of the hypoxia scan and average
blood flow and volume for the DCE CT kinetic analysis. Sec-
ond, we analysed subvolumes within the primary tumour by
selecting the regions with elevated characteristics as frequent-
ly used in previous studies. For the FDGPETscanwe used the
area with an SUV larger than 50 % of the maximum SUV: i.e.
the high FDG uptake volume [17, 29]. Hypoxic regions of the
HX4 PETscans were segmented according to threshold values
with TBRs larger than 1.2 and 1.4 [25]. For DCE CT imaging,
clear thresholds have not been defined.We therefore chose the
regions inside the tumour that were more than 50 % of the
upper first percentile. We did not choose the single voxel with
maximum blood flow or volume as the histograms turned out
to be skewed towards high values possibly also with noise that
could have influenced the maximum value. The overlaps be-
tween the various subvolumes were calculated. Since tumour
volumes have a large range between patients, we normalized
all values obtained to the volume of high FDG uptake in the
individual patient.
Statistics
Correlation coefficients were calculated using Spearman’s
correlation coefficient (MATLAB and Statistics Toolbox Re-
lease 2012b; The MathWorks, Inc., Natick, MA). Differences
among subgroups of the population were tested using the
Wilcoxon signed ranks test. Overlapping subvolumes are pre-
sented as Venn diagrams and values were normalized to the
volume defined by the high FDG uptake. P values <0.05 were
assumed to be statistically significant and averages are pre-
sented as means±standard deviation (SD).
Results
Between March 2012 and March 2014, 21 patients from the
two clinical trials mentioned above who underwent imaging
with all three modalities were included in this analysis. Pa-
tients were excluded from this analysis for various reasons:
tumour located at the diaphragm with a large motion vector
(>1 cm) as assessed on the 4D CT scan (one patient); acqui-
sition or calculation problems, e.g. too long or short delay
between injection and start of the DCE CT scan (three pa-
tients) or a calculation error in the vascular or deformation
maps (two patients); and an FDG PET scan that was not ac-
quired 1 h after injection (one patient). In total 14 patients
were identified who successfully underwent all three imaging
modalities, having a median of 2 days between all scans
(range 1–6 days). The characteristics of the patients are shown
in Table 1. An example of the various images in a patient with
a tumour in the right lower lobe is shown in Fig. 1.
Population averages and correlations
In every patient the average of the parameter of interest of
each imaging modality in the primary tumour was calculated.
Correlations between averaged perfusion and metabolic pa-
rameters, and the hypoxic fraction and hypoxic volume are
shown in Fig. 2. There were significant negative correlations
between perfusion and hypoxic parameters. There was a
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negative correlation between hypoxia TBR averaged in the
primary tumour and blood flow (−0.56, p=0.042). There were
negative correlations between hypoxic volumes defined using
TBR thresholds of 1.2 and 1.4 and blood flow (−0.65, p=
0.014, and −0.68, p=0.01 respectively). There were also sig-
nificant negative correlations between hypoxia defined using
TBR thresholds of 1.2 and 1.4 and blood volume (−0.60, p=
0.025, and −0.62, p=0.02, respectively).
Correlation coefficients between parameters from the dif-
ferent modalities are shown in Table 2. There were significant
correlations within each imaging modality, e.g. between hyp-
oxic fraction and volume for a TBR >1.2 (r=0.657, p=0.013),
between hypoxic fraction and TBR (r=0.938, p<0.001), and
between blood flow and blood volume (r=0.591, p=0.029).
There were no significant correlations between the average
FDG SUV and the hypoxic or perfusion parameters. There
were no significant correlations between maximum values of
the parameters of interest from each imaging modality except
hypoxic volume (R=0.85, p<0.001) and hypoxic fraction (R=
0.82, p<0.001) defined at a TBR >1.2, both of which were
correlated with the maximum FDG SUV. Typically, the max-
ima were at spatially distinct locations in the tumour volume
for different modalities.
Subvolume-based analysis
The average high FDG uptake subvolume was 27.6±24.3 cm3
(range 1.6 – 74.7 cm3) which was on average 24±10 % of the
primary tumour. The average hypoxic subvolume defined by
the TBR threshold >1.2 (normalized to the high FDG uptake
subvolume of the same patient) was approximately equal to
the high FDG uptake volume (98±75 %), and the hypoxic
subvolume defined by the TBR threshold >1.4 was 38±
43 %. The average normalized volume of high blood flow
and high blood volume were 58±48 % and 110±99 %, re-
spectively, again normalized to the high FDG uptake
subvolume. There was a large variation in size of the
subvolumes. The variation between the various subvolumes
and their overlap is visualized in Fig. 3 (numerical data in
Table 3). Large but not complete overlap between the hypoxic
and highmetabolic subvolumes was present. On average in all
patients the overlap of the high metabolic volume was 53±
36 % (72±27% expressed relative to the hypoxic volume) for
TBR >1.2. In patients with a hypoxic volume defined using
TBR >1.4 (nine patients) the overlap of the hypoxic volume
was 71±26 %. However, the overlaps between metabolic and
hypoxic subvolumes in the high blood flow regions of the
tumour were significantly smaller (21±21 % for TBR >1.4
and 15±17 % for TBR >1.2). The overlap between metabolic
volume
Discussion
To our knowledge this is the first study to investigate the rela-
tionships among hypoxia, metabolism and perfusion in primary
NSCLC tumours at the patient population level and also iden-
tified (non)overlapping subvolumes within the tumour.
At the population level, for the average extracted parame-
ters of the entire primary tumour, there was a negative corre-
lation (−0.5 to −0.6) between hypoxia-related parameters










Gross tumour volume (cm3)
Mean±SD (median) 149±200 (86.4)
Range 10.0 – 784
Pathology, n (%)
Adenocarcinoma 8 (57)
Squamous cell carcinoma 4 (29)
Large-cell carcinoma 2 (14)
a Oligometastatic brain metastasis, treated with curative intent
Fig. 1 Example of multiparametric imaging in a patient with NSCLC in
the right lower lobe. Left to right: CT image with the primary tumour
delineated (in red), metabolic activity imaged with FDG PET/CT,
hypoxia imaged with HX4 PET/CT, and perfusion parameters (blood
flow and blood volume) depicted with DCE CT
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(TBR, hypoxic fraction and hypoxic volume) and the perfu-
sion parameter blood flow. As shown in Fig. 2, well-perfused
tumours typically showed reduced hypoxia levels. Increased
levels of hypoxia are known from multiple studies to have a
negative effect on prognosis, and perfusion-limited hypoxia
could potentially be detected using an easily available DCE
CT imaging protocol. Also, tumours with low perfusion have
been reported to have increased potential for lymph node me-
tastases in advanced lung cancer [30]. However, in head-and-
neck cancer some investigators have reported that increased
blood flow levels are correlated with worse local control [31,
32]. In lung cancer, there is no strong evidence yet that perfu-
sion CT has a large impact on staging for diagnosis [30, 33] or
survival prediction [34], but large trials investigating outcome
are still lacking. Furthermore, no consensus exists on the op-
timal CT perfusion protocol, e.g. acquisition (timing) protocol
and contrast medium administration, making comparison be-
tween different studies difficult [35, 36].
In general, single modality investigations have focused on
one biological characteristic of the tumour only.
Multimodality imaging might provide more insight into the
tumour biology and allow detailed assessment of correlations
among tumour characteristics [37–39]. In a recent study in a
group of NSCLC patients, we showed a good correlation be-
tween hypoxic and metabolically active subvolumes in the
majority of the patients [40]. However, there were also pa-
tients with no correlation at all, and patients with a partial
mismatch between high glucose metabolism and hypoxic re-
gions. Regarding the relationship between perfusion and glu-
cose metabolism, we have previously investigated the corre-
lation between perfusion values within the highly metabolic
regions identified with an SUV larger than 50 % of the max-
imum SUV [22]. We were not able to detect any differences
between high and low/moderate FDG uptake regions. This
also holds true for the current analysis at the subvolume level
and is consistent with observations reported in the literature
[30, 41, 42].
Differences have been reported between the NSCLC sub-
types adenocarcinoma and squamous cell carcinoma regard-
ing perfusion related parameters [33] and staining of markers
of hypoxia and metabolism (e.g. CAIX, GLUT-1) in patho-
logical tumour specimens [43]. We did not find a correlation
in the subgroups among the different histological types (data
not shown) and speculate that in this study such an analysis
may have been hampered by the small size of the
subgroups.
Fig. 2 Relationships between hypoxic volumes (left two plots) and
average hypoxic TBR (right two plots) and averaged perfusion
parameters blood flow and blood volume in the primary tumour in each
patient. Hypoxic volume is defined as the volume within the primary
tumour with a TBR >1.2. Tumours with larger hypoxic volumes or
increased TBR levels have impaired blood flow
Table 2 Correlations (Spearman’s correlation coefficients) among the parameters from the different imaging modalities at the population level (14
patients)
Hypoxia PET FDG PET DCE CT
Hypoxic volume Hypoxic fraction Hypoxia (TBR) Mean SUV Blood flow Blood volume
Hypoxia PET Hypoxic volume (TBR >1.2) p=0.013 p=0.094 p=0.704 p=0.014 0.052
Hypoxic fraction (TBR >1.2) r=0.657 p<0.001 p=0.773 p=0.025 p=0.175
Hypoxia (TBR) r=0.468 r=0.938 p=0.584 p=0.042 p=0.512
FDG PET Mean SUV r=0.112 r=0.086 r=0.160 p=0.682 p=0.671
DCE CT Blood flow r=−0.653 r=−0.604 r=−0.556 r=−0.121 p=0.029
Blood volume r=−0.534 r=−0.385 r=−0.191 r=−0.125 r=0.591
Significant values are indicated in bold
For calculating the correlation coefficients, the various individual parameters (except for hypoxic volume and fraction) were averaged over the primary
tumour and represented the average value of the entire volume.
See Supplementary Table 1 for correlation coefficients and p values for the hypoxia threshold TBR >1.4
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In subvolume analysis, registration of the different datasets
is of the utmost importance. To minimize gross registration
problems we imaged all patients with the same dedicated ra-
diotherapy fixation and support systems including a flat table
top on the scanners with dedicated knee roll and arm support
systems. Taking into account that imaging was typically per-
formed within the same week, we would not have expected
large differences in patient and tumour morphology. Artefacts
due to breathing were investigated using the 4D CT scan ob-
tained during FDG PET/CT imaging for radiotherapy pur-
poses, and patients with large tumour motion were excluded
from further analysis. Residual uncertainties and small ana-
tomical differences were finally corrected using nonrigid reg-
istration that was previously validated [26–28]. Subvolumes
in this study were defined by thresholding and the subsequent
analysis used the averages within these subvolumes. This
Fig. 3 Venn diagrams showing schematically the overlap between the
high metabolic regions (FDG, red), hypoxic regions with a TBR of >1.2
(HX4, green) and increased perfusion blood flow regions (DCE CT, blue)
in each patient. The patients are ordered according to the amount of
overlap between hypoxia and blood flow. The diagram on the right
shows the average overlap volumes for all patients. Venn diagrams for
hypoxic regions defined using a TBR of >1.4 are shown in
Supplementary Fig. 1
Table 3 Overview of the average tumour subvolumes of the imaging parameters of interest, together with overlap percentages










TBR >1.2 TBR >1.4








1 107 30 12 111 92 30 6 56 6 61 3 8
2 181 55 102 190 42 9 27 50 30 63 7 13
3 107 43 17 44 67 31 7 26 2 21 0 12
4 0 0 36 175 0 0 9 67 0 0 0 0
5 125 28 10 12 71 23 1 1 2 2 0 0
6 119 46 83 79 89 40 41 38 48 44 17 14
7 12 0 87 95 12 0 29 47 0 1 0 0
8 104 59 38 36 85 55 17 13 18 17 3 5
9 35 0 26 107 28 0 2 15 4 2 0 0
10 143 98 51 77 95 76 32 54 40 63 27 41
11 172 147 28 60 98 88 15 34 25 56 18 47
12 247 24 178 407 40 11 25 64 27 54 2 3
13 24 0 32 36 23 0 5 3 0 0 0 0
14 1 0 114 106 1 0 81 76 1 1 0 0
Average±SD 98±75 38±43 58±48 110±99 53±36 26±30 21±21 39±24 15±17 28±28 6±9 4±15
Median
(range)
107 (0–247) 29 (0–147) 37 (10–178) 87 (12–407) 55 (0–98) 17 (0–88) 16 (1–81) 42 (1–76) 5 (0–48) 19 (0–63) 1 (0–27) 4 (0–47)
Results are normalized to the high FDG uptake volume (i.e. volume with an SUV >50 % of maximum SUV). The high hypoxic volume was defined as
the volumewith a TBR>1.2 or TBR >1.4; increased blood flow and blood volume levels were defined as the volumewith a flow or volume >50% of the
upper first percentile
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approach is quite robust against small errors and noise in the
image acquisition and processing for defining the boundary of
the segmentation (i.e. the edge of the subvolume). The cut-off
values applied have the greatest influence on the definition of
the subvolumes, but there is no consensus as to which values
to use. For example for hypoxia, several groups have used a
TBR cut-off value of >1.4 which implies an increase in the
background (blood pool or muscle) needs to be more than
40 % to be classified as hypoxic [40, 44–46]. Other investiga-
tors have chosen a TBR >1.2 [47, 48] or even a TBR >1.0
[49]. To our knowledge there is no current standard yet for the
definition of a hypoxic volume.
In this study we deliberately did not perform a voxel-by-
voxel analysis, because of the need for a high-precision regis-
tration technique to match the various imaging modalities. It
has been reported that misregistration of even a single voxel
can reduce correlation coefficients by 30% [39]. Furthermore,
all the statistical analysis techniques currently applied for find-
ing correlations depend on the assumption that voxels are
independent samples, whereas all the underlying imaging
techniques exhibit some sort of dependence on neighbouring
voxels due to limited resolution (e.g. FWHM of the PETscan-
ner), also calculation of p values for assessment of 10,000+
voxels will result in statistical significant correlations for clin-
ically insignificant very small non-zero correlation
coefficients.
In the subvolume analysis, there was a large variation in
overlap between different patients and tumours. In agreement
with literature [40], there was in general overlap between met-
abolically active and hypoxic volumes, whereas subvolumes
with higher blood flow did not show overlap with either met-
abolically active or hypoxic regions in the majority of the in-
vestigated patients. Findings at both the population and
subvolume levels support the hypothesis that perfusion-
limited hypoxia is related to the vasculature of the tumour [50].
In summary, at the population level we observed an inverse
correlation between perfusion-derived parameters, e.g. blood
flow and blood volume, and the severity of hypoxia as indicat-
ed by the TBR or hypoxic volume. At the tumour subvolume
level, correlations between hypoxia and metabolic parameters
of perfusion were more variable with the majority of patients
showing a spatial mismatch between highly perfused regions
and hypoxic volumes within the primary tumour. In future a
detailed assessment should be performed to identify subpopu-
lations and subvolumes that might have value for predicting
treatment outcomes (e.g. local recurrence) and might thus be
used in treatment adaptation (i.e. dose escalation).
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